Vol 72, No 4 (2021)
Clinical vignette
Published online: 2021-05-17
Clinical challenges and dilemmas in the management of advanced pancreatic neuroendocrine tumour — the first manifestation of von Hippel-Lindau disease in a young patient
1
, 2, 2, 1, 1
, 2, 2, 1, 1
Abstract
Not required for Clinical Vignette.
Keywords: pNETvon Hippel-Lindau diseasesomatostatin analogues
References
- Kos-Kudła B, Hubalewska-Dydejczyk A, Kuśnierz K, et al. Consensus Conference, olish Network of Neuroendocrine Tumours. Pancreatic neuroendocrine neoplasms - management guidelines (recommended by the Polish Network of Neuroendocrine Tumours). Endokrynol Pol. 2013; 64(6): 459–479.
- Krauss T, Ferrara AM, Links TP, et al. Preventive medicine of von Hippel-Lindau disease-associated pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2018; 25(9): 783–793.
- Falconi M, Eriksson B, Kaltsas G, et al. Vienna Consensus Conference participants. ENETS Consensus Guidelines Update for the Management of Patients with Functional Pancreatic Neuroendocrine Tumors and Non-Functional Pancreatic Neuroendocrine Tumors. Neuroendocrinology. 2016; 103(2): 153–171.
- Ahmad S, Naber MR, Giles RH, et al. Diagnostic and management strategies for pNETs in Von Hippel-Lindau: a systematic review. Endocr Relat Cancer. 2021; 28(3): 151–160.
- Stueven AK, Kayser A, Wetz C, et al. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future. Int J Mol Sci. 2019; 20(12).
